Report cover image

Insomnia Market By Therapy Type (Non pharmacological Therapy, Pharmacological Therapy): Global Opportunity Analysis and Industry Forecast, 2020-2030

Publisher Allied Market Research
Published Apr 01, 2022
Length 150 Pages
SKU # ALMR17334573

Description

Insomnia Market By Therapy Type (Non pharmacological Therapy, Pharmacological Therapy): Global Opportunity Analysis and Industry Forecast, 2020-2030

The global insomnia market was valued at $ 4,318.9 million in 2020, and is projected to reach $ 6,315.9 million by 2030, registering a CAGR of 3.9% from 2021 to 2030. Insomnia is a sleep disorder wherein people find it difficult to sleep or remain asleep. The symptoms for insomnia include, low stamina, daytime sleepiness, depression, and irritability. It is a highly prevalent disorder that affects millions of people globally. Insomnia-related conditions are caused due to disruption in circadian rhythm, chronic pain, hyperthyroidism, menopause, psychological stress, and other medical conditions. This disorder can be diagnosed in sleep laboratories by using various diagnostic devices.

The global insomnia market is expected to register substantial growth in the near future, owing to rise in depression and sleep disorders in growing number of population. For instance, according to World Health Organization (WHO), approximately 280 million population across the globe were diagnosed with depression in 2020. People diagnosed with depression usually suffer from insomnia and excessive thinking.  Furthermore, rise in stress levels among youngsters have affected the quality of sleep and hence, led to an increase in growth of the insomnia market. However, side effects caused due to excessive use of sleep medication are expected to hamper the market growth during the forecast period. Conversely, increase in funding for R&D activities in the sleep disorders sector is expected to offer remunerative opportunities for market players.

The insomnia market is segmented into therapy type and region. By therapy type, the market is categorized into non-pharmacological therapy and pharmacological therapy. Depending on non-pharmacological therapy, it is further fragmented into hypnotherapy, cognitive behavioral therapy, medical devices, and other non-pharmacological therapy. On the basis of pharmacological therapy, it is segregated into prescription sleep aids and over-the-counter sleep aids.

Region-wise, it is analyzed across North America (the U.S., Canada, Mexico) Europe (Germany, France, UK, Italy, Spain, Rest of Europe) Asia-Pacific (Japan, China, Australia, India, South Korea, Taiwan and rest of Asia-Pacific) and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).

The key players operating in the global insomnia market include, Minerva Neurosciences Inc., Currax Pharmaceuticals LLC, Eisai, Co. Ltd., Merck & Co. Inc., Pfizer, Inc., Sanofi, Takeda Pharmaceutical Company Ltd., Vanda Pharmaceuticals, Viatris (Mylan NV), and Zydus Cadila.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the insomnia market analysis from 2020 to 2030 to identify the prevailing insomnia market opportunity.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the insomnia market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
The report includes the analysis of the regional as well as global insomnia market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments


By Therapy Type

Non pharmacological Therapy
Pharmacological Therapy

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Taiwan
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Saudi Arabia
Republic Of South Africa
Rest of LAMEA

Key Market Players

CURRAX PHARMACEUTICALS LLC
EISAI, CO. LTD
merck kgaa, darmstadt, germany
MINERVA NEUROSCIENCES INC
Pfizer Inc.
Sanofi
Takeda Pharmaceutical Company Ltd
Vanda Pharmaceuticals Inc.
VIATRIS INC
zydus cadila

Table of Contents

150 Pages
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: INSOMNIA MARKET, BY THERAPY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Non pharmacological Therapy
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Pharmacological Therapy
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: INSOMNIA MARKET, BY REGION
5.1 Overview
5.1.1 Market size and forecast
5.2 North America
5.2.1 Key trends and opportunities
5.2.2 North America Market size and forecast, by Therapy Type
5.2.3 North America Market size and forecast, by country
5.2.3.1 U.S.
5.2.3.1.1 Market size and forecast, by Therapy Type
5.2.3.2 Canada
5.2.3.2.1 Market size and forecast, by Therapy Type
5.2.3.3 Mexico
5.2.3.3.1 Market size and forecast, by Therapy Type
5.3 Europe
5.3.1 Key trends and opportunities
5.3.2 Europe Market size and forecast, by Therapy Type
5.3.3 Europe Market size and forecast, by country
5.3.3.1 Germany
5.3.3.1.1 Market size and forecast, by Therapy Type
5.3.3.2 France
5.3.3.2.1 Market size and forecast, by Therapy Type
5.3.3.3 United Kingdom
5.3.3.3.1 Market size and forecast, by Therapy Type
5.3.3.4 Italy
5.3.3.4.1 Market size and forecast, by Therapy Type
5.3.3.5 Spain
5.3.3.5.1 Market size and forecast, by Therapy Type
5.3.3.6 Rest of Europe
5.3.3.6.1 Market size and forecast, by Therapy Type
5.4 Asia-Pacific
5.4.1 Key trends and opportunities
5.4.2 Asia-Pacific Market size and forecast, by Therapy Type
5.4.3 Asia-Pacific Market size and forecast, by country
5.4.3.1 Japan
5.4.3.1.1 Market size and forecast, by Therapy Type
5.4.3.2 China
5.4.3.2.1 Market size and forecast, by Therapy Type
5.4.3.3 Australia
5.4.3.3.1 Market size and forecast, by Therapy Type
5.4.3.4 India
5.4.3.4.1 Market size and forecast, by Therapy Type
5.4.3.5 South Korea
5.4.3.5.1 Market size and forecast, by Therapy Type
5.4.3.6 Taiwan
5.4.3.6.1 Market size and forecast, by Therapy Type
5.4.3.7 Rest of Asia-Pacific
5.4.3.7.1 Market size and forecast, by Therapy Type
5.5 LAMEA
5.5.1 Key trends and opportunities
5.5.2 LAMEA Market size and forecast, by Therapy Type
5.5.3 LAMEA Market size and forecast, by country
5.5.3.1 Brazil
5.5.3.1.1 Market size and forecast, by Therapy Type
5.5.3.2 Turkey
5.5.3.2.1 Market size and forecast, by Therapy Type
5.5.3.3 Saudi Arabia
5.5.3.3.1 Market size and forecast, by Therapy Type
5.5.3.4 Republic Of South Africa
5.5.3.4.1 Market size and forecast, by Therapy Type
5.5.3.5 Rest of LAMEA
5.5.3.5.1 Market size and forecast, by Therapy Type
CHAPTER 6: COMPANY LANDSCAPE
6.1. Introduction
6.2. Top winning strategies
6.3. Product Mapping of Top 10 Player
6.4. Competitive Dashboard
6.5. Competitive Heatmap
6.6. Key developments
CHAPTER 7: COMPANY PROFILES
7.1 CURRAX PHARMACEUTICALS LLC
7.1.1 Company overview
7.1.2 Company snapshot
7.1.3 Operating business segments
7.1.4 Product portfolio
7.1.5 Business performance
7.1.6 Key strategic moves and developments
7.2 EISAI, CO. LTD
7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Operating business segments
7.2.4 Product portfolio
7.2.5 Business performance
7.2.6 Key strategic moves and developments
7.3 merck kgaa, darmstadt, germany
7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Operating business segments
7.3.4 Product portfolio
7.3.5 Business performance
7.3.6 Key strategic moves and developments
7.4 MINERVA NEUROSCIENCES INC
7.4.1 Company overview
7.4.2 Company snapshot
7.4.3 Operating business segments
7.4.4 Product portfolio
7.4.5 Business performance
7.4.6 Key strategic moves and developments
7.5 Pfizer Inc.
7.5.1 Company overview
7.5.2 Company snapshot
7.5.3 Operating business segments
7.5.4 Product portfolio
7.5.5 Business performance
7.5.6 Key strategic moves and developments
7.6 Sanofi
7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Operating business segments
7.6.4 Product portfolio
7.6.5 Business performance
7.6.6 Key strategic moves and developments
7.7 Takeda Pharmaceutical Company Ltd
7.7.1 Company overview
7.7.2 Company snapshot
7.7.3 Operating business segments
7.7.4 Product portfolio
7.7.5 Business performance
7.7.6 Key strategic moves and developments
7.8 Vanda Pharmaceuticals Inc.
7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Operating business segments
7.8.4 Product portfolio
7.8.5 Business performance
7.8.6 Key strategic moves and developments
7.9 VIATRIS INC
7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Operating business segments
7.9.4 Product portfolio
7.9.5 Business performance
7.9.6 Key strategic moves and developments
7.10 zydus cadila
7.10.1 Company overview
7.10.2 Company snapshot
7.10.3 Operating business segments
7.10.4 Product portfolio
7.10.5 Business performance
7.10.6 Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL INSOMNIA MARKET, BY THERAPY TYPE, 2020-2030,($MILLION)
TABLE 2. INSOMNIA MARKET REVENUE, FOR NON PHARMACOLOGICAL THERAPY, BY REGION , 2020-2030,($MILLION)
TABLE 3. INSOMNIA MARKET NON PHARMACOLOGICAL THERAPY BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. INSOMNIA MARKET REVENUE, FOR PHARMACOLOGICAL THERAPY, BY REGION , 2020-2030,($MILLION)
TABLE 5. INSOMNIA MARKET PHARMACOLOGICAL THERAPY BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. INSOMNIA MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 7. NORTH AMERICA INSOMNIA MARKET, BY THERAPY TYPE, 2020-2030,($MILLION)
TABLE 8. NORTH AMERICA INSOMNIA MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 9. U.S. INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 10. CANADA INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 11. MEXICO INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 12. EUROPE INSOMNIA MARKET, BY THERAPY TYPE, 2020-2030,($MILLION)
TABLE 13. EUROPE INSOMNIA MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 14. GERMANY INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 15. FRANCE INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 16. UNITED KINGDOM INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 17. ITALY INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 18. SPAIN INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 19. REST OF EUROPE INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 20. ASIA-PACIFIC INSOMNIA MARKET, BY THERAPY TYPE, 2020-2030,($MILLION)
TABLE 21. ASIA-PACIFIC INSOMNIA MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 22. JAPAN INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 23. CHINA INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 24. AUSTRALIA INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 25. INDIA INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 26. SOUTH KOREA INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 27. TAIWAN INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 28. REST OF ASIA-PACIFIC INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 29. LAMEA INSOMNIA MARKET, BY THERAPY TYPE, 2020-2030,($MILLION)
TABLE 30. LAMEA INSOMNIA MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 31. BRAZIL INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 32. TURKEY INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 33. SAUDI ARABIA INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 34. REPUBLIC OF SOUTH AFRICA INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 35. REST OF LAMEA INSOMNIA MARKET BY THERAPY TYPE 2020-2030,($MILLION)
TABLE 36.CURRAX PHARMACEUTICALS LLC: COMPANY SNAPSHOT
TABLE 37.CURRAX PHARMACEUTICALS LLC: OPERATING SEGMENTS
TABLE 38.CURRAX PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
TABLE 39.CURRAX PHARMACEUTICALS LLC: NET SALES,
TABLE 40.CURRAX PHARMACEUTICALS LLC: KEY STRATERGIES
TABLE 41.EISAI, CO. LTD: COMPANY SNAPSHOT
TABLE 42.EISAI, CO. LTD: OPERATING SEGMENTS
TABLE 43.EISAI, CO. LTD: PRODUCT PORTFOLIO
TABLE 44.EISAI, CO. LTD: NET SALES,
TABLE 45.EISAI, CO. LTD: KEY STRATERGIES
TABLE 46.MERCK KGAA, DARMSTADT, GERMANY: COMPANY SNAPSHOT
TABLE 47.MERCK KGAA, DARMSTADT, GERMANY: OPERATING SEGMENTS
TABLE 48.MERCK KGAA, DARMSTADT, GERMANY: PRODUCT PORTFOLIO
TABLE 49.MERCK KGAA, DARMSTADT, GERMANY: NET SALES,
TABLE 50.MERCK KGAA, DARMSTADT, GERMANY: KEY STRATERGIES
TABLE 51.MINERVA NEUROSCIENCES INC: COMPANY SNAPSHOT
TABLE 52.MINERVA NEUROSCIENCES INC: OPERATING SEGMENTS
TABLE 53.MINERVA NEUROSCIENCES INC: PRODUCT PORTFOLIO
TABLE 54.MINERVA NEUROSCIENCES INC: NET SALES,
TABLE 55.MINERVA NEUROSCIENCES INC: KEY STRATERGIES
TABLE 56.PFIZER INC.: COMPANY SNAPSHOT
TABLE 57.PFIZER INC.: OPERATING SEGMENTS
TABLE 58.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 59.PFIZER INC.: NET SALES,
TABLE 60.PFIZER INC.: KEY STRATERGIES
TABLE 61.SANOFI: COMPANY SNAPSHOT
TABLE 62.SANOFI: OPERATING SEGMENTS
TABLE 63.SANOFI: PRODUCT PORTFOLIO
TABLE 64.SANOFI: NET SALES,
TABLE 65.SANOFI: KEY STRATERGIES
TABLE 66.TAKEDA PHARMACEUTICAL COMPANY LTD: COMPANY SNAPSHOT
TABLE 67.TAKEDA PHARMACEUTICAL COMPANY LTD: OPERATING SEGMENTS
TABLE 68.TAKEDA PHARMACEUTICAL COMPANY LTD: PRODUCT PORTFOLIO
TABLE 69.TAKEDA PHARMACEUTICAL COMPANY LTD: NET SALES,
TABLE 70.TAKEDA PHARMACEUTICAL COMPANY LTD: KEY STRATERGIES
TABLE 71.VANDA PHARMACEUTICALS INC.: COMPANY SNAPSHOT
TABLE 72.VANDA PHARMACEUTICALS INC.: OPERATING SEGMENTS
TABLE 73.VANDA PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 74.VANDA PHARMACEUTICALS INC.: NET SALES,
TABLE 75.VANDA PHARMACEUTICALS INC.: KEY STRATERGIES
TABLE 76.VIATRIS INC: COMPANY SNAPSHOT
TABLE 77.VIATRIS INC: OPERATING SEGMENTS
TABLE 78.VIATRIS INC: PRODUCT PORTFOLIO
TABLE 79.VIATRIS INC: NET SALES,
TABLE 80.VIATRIS INC: KEY STRATERGIES
TABLE 81.ZYDUS CADILA: COMPANY SNAPSHOT
TABLE 82.ZYDUS CADILA: OPERATING SEGMENTS
TABLE 83.ZYDUS CADILA: PRODUCT PORTFOLIO
TABLE 84.ZYDUS CADILA: NET SALES,
TABLE 85.ZYDUS CADILA: KEY STRATERGIES
LIST OF FIGURES
FIGURE 1.INSOMNIA MARKET SEGMENTATION
FIGURE 2.INSOMNIA MARKET,2020-2030
FIGURE 3.INSOMNIA MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.INSOMNIA MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.INSOMNIA MARKET,BY THERAPY TYPE,2020(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF NON PHARMACOLOGICAL THERAPY INSOMNIA MARKET,2020-2030(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF PHARMACOLOGICAL THERAPY INSOMNIA MARKET,2020-2030(%)
FIGURE 15.INSOMNIA MARKET BY REGION,2020
FIGURE 16.U.S. INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 17.CANADA INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 18.MEXICO INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 19.GERMANY INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 20.FRANCE INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 21.UNITED KINGDOM INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 22.ITALY INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 23.SPAIN INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 24.REST OF EUROPE INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 25.JAPAN INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 26.CHINA INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 27.AUSTRALIA INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 28.INDIA INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 29.SOUTH KOREA INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 30.TAIWAN INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 31.REST OF ASIA-PACIFIC INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 32.BRAZIL INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 33.TURKEY INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 34.SAUDI ARABIA INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 35.REPUBLIC OF SOUTH AFRICA INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 36.REST OF LAMEA INSOMNIA MARKET,2020-2030($MILLION)
FIGURE 37. TOP WINNING STRATEGIES, BY YEAR
FIGURE 38. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 39. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 40.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 41.COMPETITIVE DASHBOARD
FIGURE 42.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 43.CURRAX PHARMACEUTICALS LLC.: NET SALES ,($MILLION)
FIGURE 44.EISAI, CO. LTD.: NET SALES ,($MILLION)
FIGURE 45.MERCK KGAA, DARMSTADT, GERMANY.: NET SALES ,($MILLION)
FIGURE 46.MINERVA NEUROSCIENCES INC.: NET SALES ,($MILLION)
FIGURE 47.PFIZER INC..: NET SALES ,($MILLION)
FIGURE 48.SANOFI.: NET SALES ,($MILLION)
FIGURE 49.TAKEDA PHARMACEUTICAL COMPANY LTD.: NET SALES ,($MILLION)
FIGURE 50.VANDA PHARMACEUTICALS INC..: NET SALES ,($MILLION)
FIGURE 51.VIATRIS INC.: NET SALES ,($MILLION)
FIGURE 52.ZYDUS CADILA.: NET SALES ,($MILLION)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us